Glenmark to launch anti-hypertension drug in US, gets USFDA nod

Glenmark Pharmaceuticals will launch generic version of anti-hypertension drug telmisartan tablets in the US market following receipt of approval from the country's health regulator.

Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Ltd has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets, the company said in a filing to the BSE.

"Glenmark will commence distribution of the product immediately," it added.

The approval is for the 20 mg, 40 mg and 80 mg tablets.

Telmisartan tablets are Glenmark's generic version of Boehringer Ingelheim's Micardis. Telmisartan is indicated for the treatment of hypertension.

For the 12-month period ended March 2014, Telmisartan garnered annual sales of USD 250 million, according to IMS Health, the company said.

Glenmark's current portfolio consists of 92 products authorised for distribution in the US market and 73 ANDAs are pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 595.60 per scrip in the mid-day trade, up 1.09 per cent from the previous close on the BSE.

EDITORIAL OF THE DAY

  • India cannot afford to ignore the looming Greek crisis

    The crisis in Greece may not have a direct bearing on the Indian economy because the trading or banking exposure of Indian companies to that nation is

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Kumar Jain

A complex challenge for our PSUs

Till the mid-1990s, the central government and its companies were ...

Kuruvilla Pandikattu SJ

The transforming qualities of love

The 2015 Templeton Prize has been awarded to Canadian thinker ...

Dharmendra Khandal

The one in which a blue whale was washed ashore

Quite unexpectedly, a gigantic blue whale was washed ashore at ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture